On these bases, we conclude that the negative regulation of hypoxia/hypoxic stress could be one of the mechanisms by which atezolizumab exerts an anti-tumor effect in TNBC, suggesting a therapeutic potential for targeting PD-L1 in regulating DNA damage. Here, CD274 is linked to neoplasm.